Goldman Sachs Maintains Buy on IDEAYA Biosciences, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has reaffirmed a Buy rating on IDEAYA Biosciences (NASDAQ:IDYA) and increased the price target from $36 to $53, indicating a positive outlook on the company's stock.
January 25, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Corinne Jenkins has maintained a Buy rating on IDEAYA Biosciences and raised the price target from $36 to $53, suggesting a bullish stance on the stock.
The increase in price target by a reputable analyst from Goldman Sachs typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100